Abstract: The invention provides methods and compositions for the detection of Ehrlichia chaffeensis.

Abstract: The invention provides Ehrlichia canis antigens that can be used to detect E. canis infected animals regardless of whether the animals have been vaccinated for E. canis. The invention also provides compositions and methods for determining the presence of E. canis antigens and antibodies.

Abstract: The present invention relates to pharmaceutical compositions in the form of a gel for controlled- or sustained-release of a pharmaceutically active agent and to methods for treating or preventing a condition in an animal by administering to an animal in need thereof the pharmaceutical compositions. One particular type of condition for which the pharmaceutical compositions are useful is a microbial infection, e.g., of the skin, ear, or eye, especially for veterinary applications.

Abstract: The present invention relates to pharmaceutical compositions in the form of a gel for controlled- or sustained-release of a pharmaceutically active agent and to methods for treating or preventing a condition in an animal by administering to an animal in need thereof the pharmaceutical compositions. One particular type of condition for which the pharmaceutical compositions are useful is a microbial infection, e.g., of the skin, ear, or eye, especially for veterinary applications.

Abstract: The present invention relates to pharmaceutical compositions in the form of a gel for controlled- or sustained-release of a pharmaceutically active agent and to methods for treating or preventing a condition in an animal by administering to an animal in need thereof the pharmaceutical compositions. One particular type of condition for which the pharmaceutical compositions are useful is a microbial infection, e.g., of the skin, ear, or eye, especially for veterinary applications.

Abstract: The present invention relates to pharmaceutical compositions in the form of a gel for controlled- or sustained-release of a pharmaceutically active agent and to methods for treating or preventing a condition in an animal by administering to an animal in need thereof the pharmaceutical compositions. One particular type of condition for which the pharmaceutical compositions are useful is a microbial infection, e.g., of the skin, ear, or eye, especially for veterinary applications.

Abstract: Ehrlichia canis antigens that can be used to differentiate E. canis infected animals from animals that have been challenged with E. canis, e.g., vaccinated against E. canis, are disclosed. The invention also provides compositions and methods for determining the presence of E. canis antigens and antibodies.

Abstract: Ehrlichia canis antigens that can be used to differentiate E. canis infected animals from animals that have been challenged with E. canis, e.g., vaccinated against E. canis, are disclosed. The invention also provides compositions and methods for determining the presence of E. canis antigens and antibodies.

Abstract: A method of deriving correction for instrument-to-instrument variations in the illumination band centroid wavelengths and wavelength band shapes of the optical systems of clinical chemistry instruments includes the steps of determining the centroid wavelength and wavelength band shape of a light source used in the optical system of a clinical chemistry instrument to provide a determined wavelength band shape and centroid wavelength, comparing the determined wavelength band shape and centroid wavelength with a known reflection density or absorbance wavelength spectrum of a specific type of chemical reagent test to provide a correction value, and calculating the correction value, which is to be used to modify a reflection density or absorbance measurement taken by the instrument of a reagent test of the a specific type of chemical reagent test.

Abstract: Devices, methods and kits for conducting an assay to determine the presence or amount of an analyte in a fluid sample. The device includes a sample application element and a flow path matrix that facilitates fluidic flow by capillary action. The sample application element includes a non-absorbent or absorbent carrier that has a conjugate reagent that is readily solubilized by the liquid sample. In various aspects of the invention, the sample application element and the matrix are associated with a housing that allows for releasable contact between the element and the matrix. In other aspects, the invention includes methods using the device and kits including the device.

Abstract: A chemical analyzer includes a slide transport mechanism having a slide track adapted to hold a plurality of reagent test slides, a sample metering device, an incubator formed as a part of the slide transport mechanism to precisely maintain the temperature of the reagent test slides, a slide ejector mechanism to remove the slides from the slide transport mechanism, a sample preparation station, which includes a centrifuge, and associated electronics and software. The slide transport mechanism holds a plurality of trapezoidally-shaped reagent test slides about its circumference, which slides are loaded onto the transport mechanism by the slide inserter mechanism. The slide transport mechanism positions the reagent test slides under the sample metering device, which device deposits a predetermined volume of sample onto each slide. The slide transport mechanism also carries the slides above a reflectometer.

Abstract: Pharmaceutical compositions comprising an aptamer and an amino acid ester or amide or an aptamer; a divalent metal cation; and a carboxylic acid, a phospholipid, a phosphatidyl choline, or a sphingomyelin. Methods of treating or preventing a condition in an animal comprising administering to the animal the pharmaceutical compositions.

Abstract: A pipette tip includes a main body having an upper end, a lower end and a sidewall extending between the two ends. A bore extends axially through the main body between the upper and lower ends. The lower end has a bottom surface in which is formed a central opening that communicates with the axial bore to allow the passage of fluid therethrough. The bottom surface is formed with at least one groove that may be concentrically disposed or spirally disposed about the central opening. The at least one groove acts to inhibit fluid passing through the central opening from at least partially flowing along the outer surface of the sidewall from the central opening toward the upper end of the main body of the pipette tip.

Abstract: A device for obtaining a sample from inside a body includes a tubular body portion defining a chamber for receiving a sample of material therein; a plunger assembly operatively associated with the tubular body portion, the plunger assembly having a stopper slidably disposed within the chamber of the body portion; feedback elements provided on the tubular body and/or the plunger assembly for providing a user with audible and/or tactile indications regarding an amount of displacement of the plunger assembly relative to the body portion; and a cutting element is provided to facilitate sample removal.

Abstract: The present invention provides compositions and methods for administering florfenicol to mammals. The compositions contain a prodrug of florfenicol in a pharmaceutically acceptable carrier. In one embodiment the prodrug is an esterized form of florfenicol. Examples of suitable prodrugs include one or a combination of one or a combination of the following: florfenicol acetate, florfenicol propionate, florfenicol butyrate, florfenicol pentanoate, florfenicol hexanoate, florfenicol heptanoate, florfenicol octanoate, florfenicol nanoate, florfenicol decanoate, florfenicol undecanoate, florfenicol dodecanoate, and florfenicol phthalate. In another embodiment the prodrug is converted into the florfenicol in vivo by the action of one or more endogenous esterases. The invention also provides new compounds, pharmaceutical compositions containing the compounds, and methods for their administration.

Abstract: An article for holding a liquefied sample for the quantification of biological material in the sample includes a device having a reaction chamber enclosing a volume therein, the reaction chamber having an upper opening through which a liquefied sample can be poured and a plurality of discrete non-permeable compartments, each of the compartments having an upper rim and being configured and dimensioned to hold separate aliquots of a liquefied sample therein; and a gasket lid removably secured to the top of the device, the gasket lid being configured and dimensioned for sealing the upper rim of each compartment to prevent liquid communication between the compartments.

Abstract: A method for detecting a parasitic worm infection of the digestive tract of a mammal. The method includes detecting the binding of a worm antibody to a worm antigen present in the soluble portion of a fecal sample of infected mammals.

Abstract: A method and device for determining a feline immunodeficiency virus infection or vaccination in an animal. The method includes contacting a biological sample from a felid with various FIV polypeptides and determining the binding of antibodies in the sample to the polypeptides. The determination of whether an animal is infected with FIV or has been vaccinated against FIV can be determined by measuring the animal's immune response to an FIV env polypeptide. A device for detecting FIV antibodies is provided.

Abstract: The invention relates to pharmaceutical compositions useful for administering an oligonucleotide to an animal in need thereof. The pharmaceutical compositions include nano-particles or micro-particles of (i) a protonated oligonucleotide and (ii) a pharmaceutically acceptable organic base or include nano-particles or micro-particles of (i) an oligonucleotide and (ii) a divalent metal ion.

Abstract: The present invention is a flow cytometry-based hematology system useful in the analysis of biological samples, particularly whole blood or blood-derived samples. The system is capable of determining at least a complete blood count (CBC), a five-part white blood cell differential, and a reticulocyte count from a whole blood sample. The system preferably uses a laser diode that emits a thin beam to illuminate cells in a flow cell and a lensless optical detection system to measure one or more of axial light loss, low-angle forward scattered light, high-angle forward scattered light, right angle scattered light, and time-of-flight measurements produced by the cells. The lensless optical detection system contains no optical components, other than photoreactive elements, and does not include any moving parts. Finally, the system uses a unique system of consumable reagent tubes that act as reaction chambers, mixing chambers, and waste chambers for the blood sample analyses.